Skip to content
Screener

EyePoint, Inc. EYPT Operating Cash Flow

Operating Cash Flow at other companies

Merck & Co. logo
Merck & Co.MRK
$5.37B+63.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$813M-29.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$65.99M-47.7%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$40.01M-37.6%
Regenxbio logo
RegenxbioRGNX
-$62.24M-26.1%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$68.13M-42.6%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.11B+51.9%
Enterprise value$1.02B+49.6%
P/S396.6×+383×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Right-of-use assets and operating lease liabilities(35)543
Deferred revenue(28,637)
Other noncurrent liabilities(11)(18)
Net cash (used in) provided by operating activities(142,897)(115,709)
Cash flows from investing activities:
Purchases of marketable securities(9,949)(93,368)
Sales and maturities of marketable securities145,000182,725
Proceeds from sale of equity investment1,302

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s operating cash flow?
EyePoint, Inc. (EYPT) reported operating cash flow of -$62.35M in Q2 2026.
How has EyePoint, Inc.'s operating cash flow changed year-over-year?
EyePoint, Inc.'s operating cash flow increased by 0.4% year-over-year, from -$62.59M to -$62.35M.
What is the long-term trend for EyePoint, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), EyePoint, Inc.'s operating cash flow has grown at a 48.0% compound annual growth rate (CAGR), from -$50.1M to -$240.11M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about EyePoint, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude